HALO - Halozyme Therapeutics Inc Stock Price, Fair Value and News

$64.66-1.88 (-2.83%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

HALO Price Action

Last 7 days

-11.0%

Last 30 days

-2.3%

Last 90 days

-11.9%

Trailing 12 Months

33.4%

HALO RSI Chart

HALO Valuation

Market Cap

7.6B

Price/Earnings (Trailing)

12.77

Price/Sales (Trailing)

6.12

EV/EBITDA

10.55

Price/Free Cashflow

12.62

HALO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HALO Fundamentals

HALO Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

22.12%

Rev. Growth (Qtr)

8.76%

HALO Earnings

Earnings (TTM)

595.5M

Earnings Growth (Yr)

27.89%

Earnings Growth (Qtr)

6.09%

HALO Profitability

EBT Margin

60.02%

Return on Equity

118.17%

Return on Assets

26.81%

Free Cashflow Yield

7.92%

HALO Investor Care

Buy Backs (1Y)

7.57%

Diluted EPS (TTM)

4.75

HALO Alerts

2 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	1.1B	1.2B	1.2B	0
2024	863.0M	873.3M	947.4M	1.0B
2023	705.0M	773.7M	780.7M	829.3M
2022	471.6M	487.5M	580.6M	660.1M
2021	331.3M	412.5M	463.0M	443.3M
2020	164.4M	180.5M	199.6M	267.6M
2019	177.9M	181.9M	202.6M	196.0M
2018	317.9M	319.4M	281.2M	151.9M
2017	133.8M	134.2M	166.1M	316.6M
2016	146.7M	146.7M	146.7M	146.7M
2015	105.9M	120.8M	138.1M	146.7M
2014	54.9M	58.9M	57.5M	75.3M
2013	46.7M	53.4M	64.1M	54.8M
2012	56.0M	40.6M	22.9M	42.3M
2011	17.7M	37.7M	57.2M	56.1M
2010	0	0	0	13.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

CEO	Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
WEBSITE	https://halozyme.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	393

Halozyme Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Halozyme Therapeutics Inc? What does HALO stand for in stocks?

HALO is the stock ticker symbol of Halozyme Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Halozyme Therapeutics Inc (HALO)?

As of Wed Dec 03 2025, market cap of Halozyme Therapeutics Inc is 7.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HALO stock?

You can check HALO's fair value in chart for subscribers.

Is Halozyme Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether HALO is over valued or under valued. Whether Halozyme Therapeutics Inc is cheap or expensive depends on the assumptions which impact Halozyme Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HALO.

What is Halozyme Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, HALO's PE ratio (Price to Earnings) is 12.77 and Price to Sales (PS) ratio is 6.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HALO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Halozyme Therapeutics Inc's stock?

In the past 10 years, Halozyme Therapeutics Inc has provided 0.139 (multiply by 100 for percentage) rate of return.